A recently published report of a Phase II clinical trial conducted by the Eastern Cooperative Oncology Group (ECOG) suggests that the tyrosine kinase inhibitor (TKI) lapatinib (Tykerb) may have clinically significant effects in the treatment of men with progressive prostate cancer after first-line therapy. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: lapatinib | 3 Comments »